Publications
Find coverage of the latest original articles on Lupus, focusing on those with data on therapeutic interventions and those that have clinical impact.
This activity is supported by an educational grant from AstraZeneca.
Efficacy and Safety of Telitacicept in Patients with Systemic Lupus Erythematosus: A Multicentre, Retrospective, Real-World Study
Lupus Sci. Med. 2023;10(2):e001074 DOI 10.1136/lupus-2023-001074
In this study, telitacicept add-on therapy demonstrated desirable real-world safety and efficacy profiles for the management of SLE, LN, and patients with haematological abnormalities.
Indirect treatment comparison of anifrolumab efficacy versus belimumab in adults with systemic lupus erythematosus
J Comp Eff Res. 2022;11(10):765–777 doi: 10.2217/cer-2022-0040
Population-adjusted comparative study provides insights for decision makers and clinicians about the comparative efficacy of anifrolumab and belimumab in patients with moderate-to-severe systemic lupus erythematosus (SLE) who are receiving standard therapy.
In the absence of head-to-head comparisons, Bruce, et al. assessed the comparative efficacy of the two biological therapies currently approved in the EU and USA for the treatment of moderate-to-severe SLE (anifrolumab 300 mg and belimumab 10 mg/kg).
After adjusting for important cross-trial differences, their results showed that anifrolumab was associated with significantly greater treatment benefits than belimumab.